Product Wiki · Recalls · EU Safety Gate (RAPEX)

Ölcreme – Papillon Emu — recall 1158/07

EU Safety Gate (RAPEX) · Germany · 2007-11-09 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
1158/07
Date of alert
2007-11-09
Country / jurisdiction
Germany
Risk level
Serious risk
Risk type
Chemical
Brand
Papillon
Product category
Cosmetics
Product type
Oil cream – Papillon Emu
Reported risk: Das Produkt birgt ein chemisches Risiko, da es 34 μg/kg N-Nitrosodiethanolamin enthält. Diese Substanz wird als krebserregend für den Menschen eingestuft. Dieses Produkt entspricht nicht der Kosmetikrichtlinie 76/768/EWG.
Action taken by the authority
Type of economic operator taking notified measure
Other
Category of measure
Voluntary withdrawal from the market by the importer
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Oil cream – Papillon Emu

Risk Description (original English): The product poses a chemical risk because it contains 34 μg/kg N-Nitrosodiethanolamine. This substance is classified as human carcinogen. This product does not comply with the Cosmetics Directive 76/768/EEC.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/-12857

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.